Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Sun exposure influences the prognostic power of components of mineral metabolism in patients with coronary artery disease.

Aceña A, Franco-Peláez JA, Gutierrez-Landaluce C, Pello AM, Cristóbal C, Tarín N, Huelmos A, Carda R, Martín-Mariscal ML, Alonso J, González-Parra E, González-Casaus ML, Lorenzo Ó, López Bescos L, Egido J, Tuñón J.

Nutr Metab Cardiovasc Dis. 2017 Sep;27(9):762-767. doi: 10.1016/j.numecd.2017.06.006. Epub 2017 Jun 15.

PMID:
28803689
2.

Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease.

Pello Lázaro AM, Cristóbal C, Franco-Peláez JA, Tarín N, Aceña Á, Carda R, Huelmos A, Martín-Mariscal ML, Fuentes-Antras J, Martínez-Millá J, Alonso J, Lorenzo Ó, Egido J, López-Bescós L, Tuñón J.

PLoS One. 2017 Jan 19;12(1):e0169826. doi: 10.1371/journal.pone.0169826. eCollection 2017.

3.

Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease.

Tuñón J, Fernández-Fernández B, Carda R, Pello AM, Cristóbal C, Tarín N, Aceña Á, González-Casaus ML, Huelmos A, Alonso J, Lorenzo Ó, González-Parra E, Hernández-González I, Mahíllo-Fernández I, López-Bescós L, Egido J.

Diabetes Metab Res Rev. 2016 Oct;32(7):685-693. doi: 10.1002/dmrr.2787. Epub 2016 Apr 25.

PMID:
26888181
4.

Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate.

González-Parra E, Aceña Á, Lorenzo Ó, Tarín N, González-Casaus ML, Cristóbal C, Huelmos A, Mahíllo-Fernández I, Pello AM, Carda R, Hernández-González I, Alonso J, Rodríguez-Artalejo F, López-Bescós L, Ortiz A, Egido J, Tuñón J.

J Bone Miner Metab. 2016 Sep;34(5):587-98. doi: 10.1007/s00774-015-0706-y. Epub 2015 Aug 23.

PMID:
26298279
5.

N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease.

Tuñón J, Higueras J, Tarín N, Cristóbal C, Lorenzo Ó, Blanco-Colio L, Martín-Ventura JL, Huelmos A, Alonso J, Aceña Á, Pello A, Carda R, Asensio D, Mahíllo-Fernández I, López Bescós L, Egido J, Farré J.

PLoS One. 2015 Jun 5;10(6):e0126741. doi: 10.1371/journal.pone.0126741. eCollection 2015.

6.

The Prognostic Value of High-Sensitive Troponin I in Stable Coronary Artery Disease Depends on Age and Other Clinical Variables.

Carda R, Aceña Á, Pello A, Cristóbal C, Tarín N, Huelmos A, Alonso J, Asensio D, Lorenzo Ó, Martín-Ventura JL, Blanco-Colio L, Farré J, López Bescós L, Egido J, Tuñón J.

Cardiology. 2015;132(1):1-8. doi: 10.1159/000381259. Epub 2015 May 14.

7.

Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors.

Pello AM, Cristóbal C, Tarín N, Huelmos A, Aceña Á, Carda R, González-Casaus ML, Alonso J, Lorenzo Ó, Blanco-Colio L, Martín-Ventura JL, Franco Peláez JA, Mahíllo-Fernández I, Farré J, López-Bescós L, Egido J, Tuñón J.

J Cardiol. 2015 Jul;66(1):22-7. doi: 10.1016/j.jjcc.2014.11.006. Epub 2014 Dec 19.

8.

[Impact of plasma pro-B-type natriuretic peptide amino-terminal and galectin-3 levels on the predictive capacity of the LIPID Clinical Risk Scale in stable coronary disease].

Higueras J, Martín-Ventura JL, Blanco-Colio L, Cristóbal C, Tarín N, Huelmos A, Alonso J, Pello A, Aceña Á, Carda R, Lorenzo Ó, Mahíllo-Fernández I, Asensio D, Almeida P, Rodríguez-Artalejo F, Farré J, López Bescós L, Egido J, Tuñón J.

Clin Investig Arterioscler. 2015 Mar-Apr;27(2):57-63. doi: 10.1016/j.arteri.2014.06.003. Epub 2014 Aug 13. Spanish.

PMID:
25127747
9.

Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease.

Tuñón J, Cristóbal C, Tarín N, Aceña Á, González-Casaus ML, Huelmos A, Alonso J, Lorenzo Ó, González-Parra E, Mahíllo-Fernández I, Pello AM, Carda R, Farré J, Rodríguez-Artalejo F, López-Bescós L, Egido J.

PLoS One. 2014 Apr 18;9(4):e95402. doi: 10.1371/journal.pone.0095402. eCollection 2014.

10.

Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease.

Tuñón J, Blanco-Colio L, Cristóbal C, Tarín N, Higueras J, Huelmos A, Alonso J, Egido J, Asensio D, Lorenzo Ó, Mahíllo-Fernández I, Rodríguez-Artalejo F, Farré J, Martín-Ventura JL, López-Bescós L.

Am J Cardiol. 2014 Feb 1;113(3):434-40. doi: 10.1016/j.amjcard.2013.10.012. Epub 2013 Nov 7.

PMID:
24295549
11.

Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.

Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators.

JAMA Intern Med. 2013 Oct 14;173(18):1682-92.

PMID:
23939297
12.

Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial.

Daniels LB, Grady D, Mosca L, Collins P, Mitlak BH, Amewou-Atisso MG, Wenger NK, Barrett-Connor E; Raloxifene Use for the Heart (RUTH) Trial Investigators.

Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):164-70. doi: 10.1161/CIRCOUTCOMES.112.966986. Epub 2013 Mar 12.

13.

[Reduction in 28 days and 6 months of acute myocardial infarction mortality from 1995 to 2005. Data from PRIAMHO I, II and MASCARA registries].

Arós F, Heras M, Vila J, Sanz H, Ferreira-González I, Permanyer-Miralda G, Cuñat J, López-Bescós L, Cabadés A, Loma-Osorio A, Marrugat J; en representación de los investigadores de los registros PRIAMHO I, II y MASCARA.

Rev Esp Cardiol. 2011 Nov;64(11):972-80. doi: 10.1016/j.recesp.2011.05.011. Epub 2011 Jul 30. Spanish.

14.

Clinical scores and patient risk stratification in non-ST elevation acute coronary syndrome.

Fernández-Bergés D, Bertomeu-Gonzalez V, Sánchez PL, Cruz-Fernandez JM, Arroyo R, Barriales Álvarez V, Carrasco Sánchez FJ, Dalli E, Castro Beiras A, Kaski JC; SIESTA Study Investigators.

Int J Cardiol. 2011 Jan 21;146(2):219-24. doi: 10.1016/j.ijcard.2010.04.016. Epub 2010 May 2.

PMID:
20439123
15.

Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome.

Taglieri N, Fernandez-Berges DJ, Koenig W, Consuegra-Sanchez L, Fernandez JM, Robles NR, Sánchez PL, Beiras AC, Orbe PM, Kaski JC; SIESTA Investigators.

Atherosclerosis. 2010 Mar;209(1):300-5. doi: 10.1016/j.atherosclerosis.2009.09.022. Epub 2009 Sep 20.

PMID:
19819453
16.

Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome.

Barderas MG, Tuñón J, Dardé VM, De la Cuesta F, Jiménez-Nácher JJ, Tarín N, López-Bescós L, Egido J, Vivanco F.

Proteomics. 2009 Apr;9(7):1982-93. doi: 10.1002/pmic.200700583.

PMID:
19294693
17.

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators.

Lancet. 2008 Sep 6;372(9641):807-16. doi: 10.1016/S0140-6736(08)61170-8. Epub 2008 Aug 29.

PMID:
18757088
19.

[Microalbuminuria is also useful in staging patients with symptomatic atherosclerosis].

Guijarro C, Herreros B, Puras E, López-Bescós L.

Med Clin (Barc). 2008 May 31;130(20):799. Spanish. No abstract available.

PMID:
18579039
20.

Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome.

Gómez-Hernández A, Sánchez-Galán E, Ortego M, Martín-Ventura JL, Blanco-Colio LM, Tarín-Vicente N, Jiménez-Nacher JJ, López-Bescos L, Egido J, Tuñón J.

Am J Cardiol. 2008 Jul 1;102(1):12-8. doi: 10.1016/j.amjcard.2008.02.090. Epub 2008 Apr 22.

PMID:
18572029

Supplemental Content

Loading ...
Support Center